Analysts Set Epizyme Inc (EPZM) PT at $23.10

Shares of Epizyme Inc (NASDAQ:EPZM) have earned an average rating of “Buy” from the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and seven have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $23.10.

Several research analysts have recently issued reports on EPZM shares. ValuEngine lowered Epizyme from a “sell” rating to a “strong sell” rating in a research report on Monday, April 9th. BidaskClub lowered Epizyme from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 3rd. Wedbush increased their target price on Epizyme from $20.00 to $25.00 in a research report on Friday, May 18th. Leerink Swann set a $24.00 target price on Epizyme and gave the stock a “buy” rating in a research report on Tuesday, April 24th. Finally, SunTrust Banks decreased their target price on Epizyme to $20.00 and set a “hold” rating for the company in a research report on Tuesday, April 24th.

Institutional investors have recently bought and sold shares of the stock. Macquarie Group Ltd. grew its stake in shares of Epizyme by 100.7% in the 4th quarter. Macquarie Group Ltd. now owns 82,485 shares of the biopharmaceutical company’s stock worth $1,035,000 after buying an additional 41,385 shares during the last quarter. BlackRock Inc. boosted its stake in Epizyme by 17.1% during the 4th quarter. BlackRock Inc. now owns 3,965,391 shares of the biopharmaceutical company’s stock valued at $49,766,000 after purchasing an additional 579,662 shares during the last quarter. Millennium Management LLC boosted its stake in Epizyme by 56.4% during the 4th quarter. Millennium Management LLC now owns 996,687 shares of the biopharmaceutical company’s stock valued at $12,508,000 after purchasing an additional 359,547 shares during the last quarter. University of Notre Dame DU Lac boosted its stake in Epizyme by 6.7% during the 4th quarter. University of Notre Dame DU Lac now owns 204,600 shares of the biopharmaceutical company’s stock valued at $2,568,000 after purchasing an additional 12,881 shares during the last quarter. Finally, Palo Alto Investors LP boosted its stake in Epizyme by 0.5% during the 1st quarter. Palo Alto Investors LP now owns 6,895,075 shares of the biopharmaceutical company’s stock valued at $122,388,000 after purchasing an additional 34,232 shares during the last quarter. Institutional investors own 85.22% of the company’s stock.

Epizyme traded down $0.20, reaching $14.80, during midday trading on Tuesday, according to MarketBeat.com. 1,141,687 shares of the company’s stock traded hands, compared to its average volume of 419,144. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -6.79 and a beta of 2.09. Epizyme has a 52 week low of $11.15 and a 52 week high of $21.40.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05. During the same period in the prior year, the business posted ($0.56) EPS. analysts anticipate that Epizyme will post -2.22 earnings per share for the current fiscal year.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply